

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-6 (canceled)

7. (Currently Amended) A method of treatment of a patient with a disease caused by virions comprising: administering the patient a nucleic acid-binding chemotherapeutic agent which complexes a metal ion, thereby yielding a complex that promotes formation of hydroxyl radicals from hydrogen peroxide, said nucleic acid-binding chemotherapeutic agent being bleomycin.

~~;~~ and

~~— administering the patient an iron-chelating compound that is unable to promote the formation of hydroxyl radicals from hydrogen peroxide.~~

8. (Canceled) A method according to claim 7 wherein the nucleic acid-binding chemotherapeutic agent is selected from the group consisting of bleomycin and adriamycin.

9. (Currently Amended) A method according to claim 8 7 wherein the nucleic acid-binding chemotherapeutic agent is used for the treatment of a disease caused by an RNA virus.

10. (Previously Added) A method according to claim 9 wherein the nucleic acid-binding chemotherapeutic agent is used for the treatment of a disease caused by HIV.

11. (Withdrawn) A pharmaceutical composition comprising:
a nucleic acid-binding chemotherapeutic agent comprising a metal ion complexed therewith, which complex promotes the formation of hydroxyl radicals from hydrogen peroxide *in vivo*; and a pharmaceutically acceptable carrier or excipient, which comprises an iron-chelating compound which

binds iron in a form in which such chelated iron is unable to promote the formation of hydroxyl radicals from hydrogen peroxide.

12. (Withdrawn) A pharmaceutical combination composition according to claim 11 wherein the iron-chelating compound has an iron-chelating capacity which is at least three times lower than that of the nucleic acid-binding chemotherapeutic agent.

13. (Withdrawn) A pharmaceutical combination composition according to claim 11 wherein the iron-chelating compound has an iron-chelating capacity which is at least ten times lower than that of the nucleic acid-binding chemotherapeutic agent.

14. (Canceled) A method according to claim 7 wherein the nucleic acid-binding chemotherapeutic agent and the iron-chelating compound are administered simultaneously.

15. (Canceled) A method according to claim 7 wherein the iron-chelating compound has an iron-chelating capacity which is at least three times lower than that of the nucleic acid-binding chemotherapeutic agent.

16. (Canceled) A method according to claim 15 wherein the iron-chelating compound has an iron-chelating capacity which is at least ten times lower than that of the nucleic acid-binding chemotherapeutic agent.

17. (Currently Amended) A method of treatment of a disease caused by an RNA virus, comprising administering bleomycin to a patient infected with the RNA virus, ~~wherein the patient does not have Kaposi's sarcoma or lymphoma.~~

18. (Previously Added) The method of claim 17 wherein the disease caused by an RNA virus is HIV.

19. (Canceled) The method of claim 17, further comprising administration of an iron-chelating compound that is unable to promote the formation of hydroxyl radicals from hydrogen peroxide.

20. (Canceled) The method of claim 19 wherein the iron-chelating compound has an iron-chelating capacity which is at least three times lower than that of bleomycin.

21. (Canceled) The method of claim 19 wherein the iron-chelating compound has an iron-chelating capacity which is at least ten times lower than that of bleomycin.